Ivan Kairatov is a biopharma expert with a track record bridging preclinical discovery and translational development across oncology subtypes. He has worked at the interface of receptor biology, pharmacology, and clinical trial design, and he brings a pragmatic lens to drug repurposing. In this
Could a single seed pull double duty against inflammation, oxidative stress, microbes, and metabolic drift without the side-effect ledger that shadows many prescriptions, and could it do so in a way that complements rather than competes with standard care? That is the provocation driving a surge of
Imagine a silent epidemic affecting thousands of men each year, often undetected until it’s too late, with societal norms discouraging open conversations about personal health challenges, and prostate cancer standing as the most common cancer among men in the UK, with around 55,000 new cases
In a remarkable advancement that could alter the landscape of cancer care, researchers from University College London (UCL) and the University of Oxford have developed LungVax, the world’s first experimental vaccine aimed at preventing lung cancer. This pioneering initiative, now entering clinical
Imagine a scenario where a patient diagnosed with metastatic colorectal cancer (CRC) receives a treatment that not only halts the disease's progression but also leads to remarkable tumor shrinkage, offering a renewed chance at life. This isn’t just a hopeful vision but a reality for a small subset
The landscape of oncology treatment is witnessing a transformative shift with Johnson & Johnson (J&J) securing a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for its groundbreaking therapy, TALVEY (talquetamab). This approval for use within the
